Back to results

CompletedPhase 3

Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes

NCT01562561

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Novo Nordisk Investigational Site

Shatin, New Territories, Hong Kong

+11 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2001-06-01
Enrollment: 213 participants
Sponsor: Novo Nordisk A/S
Purpose: treatment

Locations (12)

Novo Nordisk Investigational SiteShatin, New Territories, Hong Kong
Novo Nordisk Investigational SiteKota Bharu, Kelantan, Malaysia
Novo Nordisk Investigational SiteMarikina City, Philippines
Novo Nordisk Investigational SitePasig, Philippines
Novo Nordisk Investigational SiteQuezon City, Philippines
Novo Nordisk Investigational SiteJohannesburg, Gauteng, South Africa
Novo Nordisk Investigational SitePretoria, Gauteng, South Africa
Novo Nordisk Investigational SiteDurban, KwaZulu-Natal, South Africa
Novo Nordisk Investigational SiteBrits, North West, South Africa
Novo Nordisk Investigational SiteCape Town, Western Cape, South Africa
Novo Nordisk Investigational SiteAlberton, South Africa
Novo Nordisk Investigational SiteTainan, Taiwan

Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes — TrialFind